Shree Radhey Gobind International Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 112.00%
- Profit Growth 280.01%
- Ebitda 727.25%
- Net Worth 266.09%
- Total Assets 35.30%
About Shree Radhey Gobind International Pharmaceuticals
Shree Radhey Gobind International Pharmaceuticals Private Limited (SRGIPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 November 2015 (Nine years and two months 9 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51900DL2015PTC287883
-
Company No.
287883
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Nov 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Shree Radhey Gobind International Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Sakhuja
|
Director | 26-Sep-2019 | Current |
|
Keshav Bajaj
|
Director | 24-Feb-2022 | Current |
Financial Performance of Shree Radhey Gobind International Pharmaceuticals.
Shree Radhey Gobind International Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 112% increase. The company also saw a substantial improvement in profitability, with a 280.01% increase in profit. The company's net worth Soared by an impressive increase of 266.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shree Radhey Gobind International Pharmaceuticals?
In 2019, Shree Radhey Gobind International Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Wifitics India Private LimitedKeshav Bajaj is a mutual person
-
Girivara Exports Private LimitedKeshav Bajaj is a mutual person
-
Okhly Herbals Private Limited
Gaurav Sakhuja is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shree Radhey Gobind International Pharmaceuticals?
Unlock and access historical data on people associated with Shree Radhey Gobind International Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shree Radhey Gobind International Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Radhey Gobind International Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
